LOW-QUEL
Clinical safety rating
cautionComprehensive clinical and safety monograph for LOW-QUEL (LOW-QUEL).
Low-Quel is a combination product containing an opioid agonist and a non-opioid analgesic. The opioid component acts on mu-opioid receptors in the central nervous system to alter pain perception, while the non-opioid component inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing additive analgesia.
| Metabolism | The opioid component is primarily metabolized by CYP3A4 and CYP2D6, with conjugation as a minor pathway. The non-opioid analgesic is extensively metabolized in the liver via glucuronidation and sulfation, with minor contributions from CYP450 enzymes. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of elimination; hepatic metabolism accounts for 20-30% (primarily CYP3A4); biliary/fecal excretion of metabolites accounts for <10%. |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults; increases to 20-24 hours in hepatic impairment and 18-22 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 94-97% bound to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 4-6 L/kg, indicating extensive tissue distribution (e.g., lung, liver, kidney, brain). |
| Bioavailability | Oral bioavailability is 70-80% (first-pass metabolism reduces from 95% absorption); bioavailability is reduced by 20-30% with high-fat meal. |
| Onset of Action | Oral: 1-2 hours (peak plasma concentration at 3-5 hours). |
| Duration of Action | Duration of therapeutic effect is 8-12 hours after a single oral dose; steady-state achieved within 3-5 days; clinical effect persists for 12-24 hours after discontinuation due to slow elimination. |
| Molecular Weight | 340.46 |
10 mg orally twice daily; not to exceed 20 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: 10 mg once daily; GFR 15-29 mL/min: 5 mg once daily; GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | 0.2 mg/kg orally twice daily; maximum 10 mg/day. |
| Geriatric use | Initial 5 mg orally once daily; titrate cautiously to 10 mg/day. |
| 1st trimester | Risk summary: Inadequate human data; animal studies not available. Avoid use due to potential teratogenicity based on mechanism of action. |
| 2nd trimester | Risk summary: No human data; potential fetal harm based on pharmacodynamics. Use only if benefit outweighs unknown risk. |
| 3rd trimester | Risk summary: Risk of neonatal complications (e.g., withdrawal, respiratory depression) if used near term. Avoid use in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for LOW-QUEL (LOW-QUEL).
| Placental transfer | Low molecular weight suggests transfer; specific data unavailable. Likely crosses placenta based on physicochemical properties. |
| Breastfeeding | No published data on excretion in milk. Due to low molecular weight, likely to transfer. Monitor infant for sedation and respiratory depression. Consider alternative agents. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | No adequate human studies; animal studies not available. First trimester risk unknown; second and third trimester: potential for fetal hyperinsulinemia and hypoglycemia if used near term. |
| Fetal Monitoring | Monitor maternal blood glucose, fetal growth ultrasound, and neonatal blood glucose at delivery. |
| Fertility Effects | No specific data on fertility; theoretical potential for hormonal effects that may impact ovulation. |
■ FDA Black Box Warning
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from the non-opioid component.
| Serious Effects |
Known hypersensitivity to LOW-QUELSevere hepatic impairmentConcurrent use with MAOIsBreastfeeding (relative)
| Precautions | Life-threatening respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity; gastrointestinal bleeding; renal impairment; seizures; and serotonin syndrome. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase quetiapine levels. Take with a light meal to reduce GI upset. Avoid high-fat meals when taking extended-release formulations. |
| Clinical Pearls | LOW-QUEL is a low-dose quetiapine formulation (e.g., 25-50 mg) used off-label for insomnia. Monitor for somnolence, orthostatic hypotension, and weight gain. Avoid in patients with QTc prolongation or uncontrolled diabetes. Taper slowly after long-term use to avoid rebound insomnia. |
| Patient Advice | Take exactly as prescribed, usually 1-2 hours before bedtime. · Do not drive or operate machinery until you know how this drug affects you. · Avoid alcohol and other sedatives while taking this medication. · Report any fainting, fast heartbeat, or unusual movements to your doctor. · Do not stop suddenly; dosages must be tapered gradually. |
Loading safety data…